Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA ’ s steps on naming of biological medicines to balance competition and safety for patients receiving these products

FDA updates draft guidance to set a clear path for the nonproprietary naming of interchangeable biosimilars.
Source: Food and Drug Administration - Category: American Health Source Type: news